Structure–activity relationships of GSK-3β inhibitors for Alzheimer's disease.
Structure–activity relationships for isonicotinamide-based GSK-3β inhibitors were established. Newly designed compounds 3X and 9X were found to be potential GSK-3β inhibitors and merit further exploration.
Herein, we show that protein degraders represent a significant step forward in modulating protein kinases involved in Alzheimer's disease, given the many advantages of protein degradation over classical inhibition.
Effective 3D-QSAR models, molecular docking, molecular dynamics were employed for novel oxadiazole derivatives, the derived structural information will be helpful in the designing of novel ligands with more potent activity.
New phosphazine and triazole derivatives were synthesized and evaluated as potential anti-Alzheimer's agents. The compounds modulate ROS/JNK and Wnt/β-catenin pathways, showing promising neuroprotective activities.